Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-01-18, Stock:LLY, The news for the past five days is as follows:
2019-01-11: NEWS1: 5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019.NEWS2: Stock Market Rally Runs Into Resistance; Boeing, GM, Macy's, American Airlines: Weekly Review.NEWS3: Lilly eyes more cancer deals, but wary of CAR-T, gene therapy.NEWS4: 7 Pharmaceutical Stocks That Just Raised Prices This Year.NEWS5: The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock.NEWS6: The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock.NEWS7: Why Aratana Therapeutics Inc. Is Tumbling Today.NEWS8: Why Aratana Therapeutics Inc. Is Tumbling Today.NEWS9: Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why.NEWS10: Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why.NEWS11: Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet.NEWS12: Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet.NEWS13: iShares Edge MSCI USA Momentum Factor ETF Experiences Big Outflow.NEWS14: iShares Edge MSCI USA Momentum Factor ETF Experiences Big Outflow.NEWS15: Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why.NEWS16: Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference.NEWS17: Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference.NEWS18: The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock.NEWS19: Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet.NEWS20: The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference.NEWS21: The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference.NEWS22: The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference.NEWS23: 4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019.
2019-01-14: NEWS1: Eli Lilly CEO Predicts 2019 Will Be Big Year for Biotech Acquisitions.NEWS2: Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know.NEWS3: Will Biogen Jump On This Biotech Stock Amid Buying Spree?.NEWS4: House Democrats launch drug-pricing probe into a dozen major health-care companies.NEWS5: Here's Why Eli Lilly Stock Surged 37% in 2018.NEWS6: Here's Why Eli Lilly Stock Surged 37% in 2018.
2019-01-15: NEWS1: Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter.NEWS2: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders.NEWS3: Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer.NEWS4: Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer.NEWS5: Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer.NEWS6: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS7: Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know.NEWS8: Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know.
2019-01-16: NEWS1: 5 Health Care Stocks in Gurus' Portfolios.NEWS2: Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings.NEWS3: Intrexon Signs Licensing Agreement with Next Green Wave.NEWS4: Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It.NEWS5: Goldman's Gold Standard in M&A Bolsters Outlook for 2019.NEWS6: Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming.NEWS7: 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019.NEWS8: 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019.NEWS9: 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019.
2019-01-17: NEWS1: FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz.NEWS2: FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz.NEWS3: Lilly&apos;s 10-Day Sprint For Loxo Could Put Other Names On The Table.NEWS4: Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table.NEWS5: Ligand (LGND) Takes a Hit on Citron's Negative Research Report.NEWS6: Citron Says Ligand Has 80% Downside in Explosive Note.NEWS7: Dealmaking surge confirms the stock market got far too ch....NEWS8: Jim Cramer: There's a Ton More Deals in the Pipe.

Answer: Decrease